Cargando…

Seronegative Obstetric Antiphospholipid Syndrome Finally Treated Successfully

We report the case of a 31-year-old woman with a history suggestive of obstetric antiphospholipid syndrome (APS) with recurrent miscarriages, preterm labour and intrauterine fetal death. During her last pregnancy, she was referred to the Rheumatology Clinic at King Fahad Military Medical Complex, Dh...

Descripción completa

Detalles Bibliográficos
Autores principales: Alghanim, Khawla K, Alrayes, Hezab A, Aljurbua, Rayan M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SMC Media Srl 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9829023/
https://www.ncbi.nlm.nih.gov/pubmed/36632543
http://dx.doi.org/10.12890/2022_003686
_version_ 1784867389824827392
author Alghanim, Khawla K
Alrayes, Hezab A
Aljurbua, Rayan M
author_facet Alghanim, Khawla K
Alrayes, Hezab A
Aljurbua, Rayan M
author_sort Alghanim, Khawla K
collection PubMed
description We report the case of a 31-year-old woman with a history suggestive of obstetric antiphospholipid syndrome (APS) with recurrent miscarriages, preterm labour and intrauterine fetal death. During her last pregnancy, she was referred to the Rheumatology Clinic at King Fahad Military Medical Complex, Dhahran, Saudi Arabia. Serology for connective tissue diseases and APS was negative on multiple occasions. During previous pregnancies, her obstetrician had initiated several trials of baby aspirin with and without prophylactic heparin, without success. We diagnosed her with seronegative obstetric APS (SN-APS). A specific regimen, consisting of combination therapy with baby aspirin, low-molecular-weight heparin, hydroxychloroquine (<5 mg/kg/day) and low-dose prednisolone, was attempted. She delivered a healthy baby even though it was born preterm at 30 weeks of gestation because of abruptio placentae. Obstetric SN-APS is rare and should be considered and, if the history is highly suggestive, treated similarly to seropositive obstetric APS to reduce mortality. LEARNING POINTS: Seronegative antiphospholipid syndrome (SN-APS) is very rare and often missed clinically. SN-APS should be treated similarly to seropositive obstetric APS to reduce recurrence. The antimalarial drug hydroxychloroquine should be considered 3 months before attempts at conception as it appears to decrease antiphospholipid levels.
format Online
Article
Text
id pubmed-9829023
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SMC Media Srl
record_format MEDLINE/PubMed
spelling pubmed-98290232023-01-10 Seronegative Obstetric Antiphospholipid Syndrome Finally Treated Successfully Alghanim, Khawla K Alrayes, Hezab A Aljurbua, Rayan M Eur J Case Rep Intern Med Article We report the case of a 31-year-old woman with a history suggestive of obstetric antiphospholipid syndrome (APS) with recurrent miscarriages, preterm labour and intrauterine fetal death. During her last pregnancy, she was referred to the Rheumatology Clinic at King Fahad Military Medical Complex, Dhahran, Saudi Arabia. Serology for connective tissue diseases and APS was negative on multiple occasions. During previous pregnancies, her obstetrician had initiated several trials of baby aspirin with and without prophylactic heparin, without success. We diagnosed her with seronegative obstetric APS (SN-APS). A specific regimen, consisting of combination therapy with baby aspirin, low-molecular-weight heparin, hydroxychloroquine (<5 mg/kg/day) and low-dose prednisolone, was attempted. She delivered a healthy baby even though it was born preterm at 30 weeks of gestation because of abruptio placentae. Obstetric SN-APS is rare and should be considered and, if the history is highly suggestive, treated similarly to seropositive obstetric APS to reduce mortality. LEARNING POINTS: Seronegative antiphospholipid syndrome (SN-APS) is very rare and often missed clinically. SN-APS should be treated similarly to seropositive obstetric APS to reduce recurrence. The antimalarial drug hydroxychloroquine should be considered 3 months before attempts at conception as it appears to decrease antiphospholipid levels. SMC Media Srl 2022-12-05 /pmc/articles/PMC9829023/ /pubmed/36632543 http://dx.doi.org/10.12890/2022_003686 Text en © EFIM 2022 https://creativecommons.org/licenses/by-nc-nd/4.0/This article is licensed under a Commons Attribution Non-Commercial 4.0 License (https://creativecommons.org/licenses/by-nc-nd/4.0/)
spellingShingle Article
Alghanim, Khawla K
Alrayes, Hezab A
Aljurbua, Rayan M
Seronegative Obstetric Antiphospholipid Syndrome Finally Treated Successfully
title Seronegative Obstetric Antiphospholipid Syndrome Finally Treated Successfully
title_full Seronegative Obstetric Antiphospholipid Syndrome Finally Treated Successfully
title_fullStr Seronegative Obstetric Antiphospholipid Syndrome Finally Treated Successfully
title_full_unstemmed Seronegative Obstetric Antiphospholipid Syndrome Finally Treated Successfully
title_short Seronegative Obstetric Antiphospholipid Syndrome Finally Treated Successfully
title_sort seronegative obstetric antiphospholipid syndrome finally treated successfully
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9829023/
https://www.ncbi.nlm.nih.gov/pubmed/36632543
http://dx.doi.org/10.12890/2022_003686
work_keys_str_mv AT alghanimkhawlak seronegativeobstetricantiphospholipidsyndromefinallytreatedsuccessfully
AT alrayeshezaba seronegativeobstetricantiphospholipidsyndromefinallytreatedsuccessfully
AT aljurbuarayanm seronegativeobstetricantiphospholipidsyndromefinallytreatedsuccessfully